John Geisler, PhD

Mitochon Pharmaceuticals

John G. Geisler, Ph.D., Founder & Chief Scientific Officer – Dr. Geisler comes with 25+ years of research experience with a consistent pharmacological focus of trying to work at the root of problems; 15-years focused on metabolic drug discovery for Pfizer, Ionis, and Johnson & Johnson Pharmaceutical Research and Development (J&J PRD). Dr. Geisler has expertise in mitochondrial energy expenditure from years of attempting to partition lipids to restore insulin sensitivity and reduce the comorbidities associated with the “over-nutritional phenotype” (Geisler, J.G. Diabetologia 2011). From this work, stemmed a broader understanding of new mitochondrial targeted applications, and significant gaps of pharmacological interventions for insidious movement disorders and neurodegenerative diseases. Dr. Geisler is the author of over 50 papers & abstracts, and the co-inventor on a number of patents. Dr. Geisler holds a Ph.D. in Mammalian Genetics from University of Tennessee, conducted at Oak Ridge National Laboratories (ORNL), with a dissertation on the characterization of a novel muscle protein with dystrophin-like characteristics. His fellowship at Yale University, focused on the protective effects of E2 related to diabetic sexual dimorphism, by studying islet biology, physiology and whole-body flux.

Publications

First published on: December 06, 2022

Last modified on: March 28, 2024